Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity (EPIC-HIPC)
Sponsor: Boston Children's Hospital
Listed as NCT03246230, this NA trial focuses on Newborn Vaccine Immunogenicity and remains completed. Sponsored by Boston Children's Hospital, it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2024 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Feb 2023 — Jan 2024 [monthly]
Active Not Recruiting NA
▶ Show 11 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting NA
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2022 — Apr 2022 [monthly]
Recruiting NA
-
Feb 2021 — Jan 2022 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2020 — Sep 2020 [monthly]
Recruiting NA
-
Dec 2018 — Feb 2020 [monthly]
Recruiting NA
-
Jun 2018 — Dec 2018 [monthly]
Recruiting NA
-
Nov 2017 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Nov 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Children's Hospital
- Institute for Medical Research, Papua New Guinea
- Medical Research Council Unit, The Gambia
- The University of Western Australia
- University of British Columbia
For direct contact, visit the study record on ClinicalTrials.gov .